Eli Lilly to acquire Merida Biosciences for up to $2.875 billion, bolstering its immunology pipeline

Eli Lilly announced a deal to purchase Merida Biosciences, a biotech focused on immunology, for a total consideration that could reach $2.875 billion.

The acquisition adds Merida's assets in fast-growing subfields of immunology to Lilly's existing portfolio, strengthening its pipeline in that therapeutic area.

This transaction is Lilly's thirteenth acquisition in 2026, highlighting the company's aggressive strategy to expand its presence in the immunology market.